|
INTERNATIONAL JOURNAL OF SCIENTIFIC DEVELOPMENT AND RESEARCH International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2455-2631 | Impact factor: 8.15 | ESTD Year: 2016 open access , Peer-reviewed, and Refereed Journals, Impact factor 8.15 |
Imp Links for Author
Imp Links for Reviewer
Research Area
Subscribe IJSDR
Visitor Counter
Copyright Infringement Claims
Indexing Partner
|
Published Paper Details
|
|
| Paper Title: | A PROSPECTIVE, OBSERVATIONAL STUDY OF ADVERSE EFFECTS AND CLINICAL OUTCOMES OF TICAGRELOR. |
| Authors Name: | Nisma Siddiqi , Madiha Naaz , Amini Raunaq Fatima , A. Srinivas Rao , A.V.Kishore Babu |
| Unique Id: | IJSDR2303174 |
| Published In: | Volume 8 Issue 3, March-2023 |
| Abstract: | Even after the advancement in treatment of Acute Coronary Syndrome, it remains life-threatening. The standard therapy for treatment of ACS is dual antiplatelet therapy which includes combination of P2Y12 receptor antagonist along with aspirin. Ticagrelor is a drug which is a P2Y12 receptor antagonist belonging to the class cyclopentyltriazolopyrimidines.The study was conducted in AIG Hospitals, Gachibowli for a period of 6 months. A total of 85 patients of different age groups were considered. Out of 85 patients, 70 (82%) were found to be males and 15 (18%) was found to be females. The patients with age group ranging from 46-60 years which is late middle aged in both males and females were suffering from ACS. It has been shown that 35 males among 70 and 6 females among 15 were in the age group of 46-60 years to whom ticagrelor was prescribed after the stent was placed. Among 85 patients only 21.1% patients showed obesity. Among 85 patients 54 patients had hypertension, 45 patients had diabetes mellitus. Around 11% ,7% , and 3.5% patients showed dyspnea, bleeding and bradycardia respectively, these adverse effects were assessed using Naranjo’s casualty assessment scale. Drug discontinuation was also seen in 6 patients because of the adverse effects. Around 6% patients were re-hospitalized while on the drug Ticagrelor. From this study, it was concluded that maximum number of patients suffering from ACS are males, in the age group of 46-60 yrs. NSTEMI contributes maximum number of cases among the total cases. ADR’s were seen in 17 patients which were related with increased concentration of endogenous adenosine. Though the drug was discontinued in 3 patients because of severe dyspnea. Bleeding was reported in very few cases out of which 1 patient showed severe epistaxis and 2 patients showed severe brown spots; as a result, the drug was discontinued. Maximum number of ADR’s where seen in male patients and patients with co-morbidities. Re-hospitalization was seen in 5 patients during our study. |
| Keywords: | cyclopentyltriazolopyrimidines, acute coronary syndrome, antiplatelet, Naranjo’s casualty assessment scale, NSTEMI. |
| Cite Article: | "A PROSPECTIVE, OBSERVATIONAL STUDY OF ADVERSE EFFECTS AND CLINICAL OUTCOMES OF TICAGRELOR. ", International Journal of Science & Engineering Development Research (www.ijsdr.org), ISSN:2455-2631, Vol.8, Issue 3, page no.1058 - 1067, March-2023, Available :http://www.ijsdr.org/papers/IJSDR2303174.pdf |
| Downloads: | 000337070 |
| Publication Details: | Published Paper ID: IJSDR2303174 Registration ID:204416 Published In: Volume 8 Issue 3, March-2023 DOI (Digital Object Identifier): Page No: 1058 - 1067 Publisher: IJSDR | www.ijsdr.org ISSN Number: 2455-2631 |
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijsdr.org
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | DOAJ : Directory of Open Access Journals |
| DRJI | Index Copernicus International | Scribd | DocStoc |
Track Paper
Important Links
Conference Proposal
ISSN
 |
 |
DOI (A digital object identifier)
  Providing A digital object identifier by DOI How to GET DOI and Hard Copy Related |
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
 |
 |
 |
Social Media
Indexing Partner |
|||
| Copyright © 2024 - All Rights Reserved - IJSDR | |||
Facebook Twitter Instagram LinkedIn